fbpx

molecules of the month

Remibrutinib

BTK-selective covalent kinase inhibitor

Ph. I completed in HV, in Ph. II

SBDD from reversible BTK inhibitor and opt.

J. Med. Chem., Mar. 4, 2020

Novartis, Basel, CH

Structure of BTK inhibitor Remibrutinib
1 min read

Remibrutinib (Novartis oral BTK-selective covalent kinase inhibitor clinical candidate)


request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.


already a member? log in: